Kyle founded ETTA Biotechnology to create the most effective treatments targeting aging currently possible. The first therapies he designed have the potential to extend healthy human lifespan by 30+ years based on preclinical mouse studies and have seen safety, bioactivity, and hints of efficacy in human case studies.
Kyle is a scientist and entrepreneur with >15 years of expertise in aging and biotechnology, with a special focus on delivery of small molecules, DNA, mRNA, and proteins to extend lifespan.
Kyle researched synaptic vesicle exocytosis in collaboration with Nobel Prize winner Thomas Südhof during his PhD in biophysics at the University of Texas Southwestern. He also investigated how circulating proteins in the bloodstream can influence the aging brain during his postdoc at Stanford in the lab of Tony Wyss-Coray collaborating with Nobel Prize winner Carolyn Bertozzi.
Chief Executive Officer, Ainnocence
Expert in using AI to generate novel molecules that outperform existing real world molecules.
Assistant Professor, University of Minnesota
Discovered the natural molecule fisetin is a senotherapeutic and can extend lifespan.
Chief Executive Officer, Crescendo Health
Demonstrated success in building healthcare businesses. Founder of Datavant, a unicorn company with focus on clinical data analytics. MBA from Stanford Business School